Maureen Ferran
Professor
Maureen Ferran
Professor
Education
BS, Fordham University; MS, Ph.D., University of Connecticut
Bio
Maureen Ferran earned her M.S. and Ph.D. in Genetics from the University of Connecticut, where she studied how viruses evade the host innate immune response. She then went to the Laboratory of Viral Genetics within the National Institute of Allergy and Infectious Disease at the National Institutes of Health, where she studied human papillomavirus.
She is now an associate professor in the Thomas H. Gosnell School of Life Sciences at the Rochester Institute of Technology in Rochester NY where she teaches courses including Virology, Infectious Disease: Impact on Society and Culture, and Eukaryotic Gene Regulation and Disease.
Her research lab focuses on the development of viruses as a cancer therapy and as a molecular tool to understand innate immunity and age-related diseases. Studies in her lab also investigate the use of imaging agents to detect and target breast cancer.
Select Scholarship
Currently Teaching
In the News
-
February 24, 2025
Researchers explore how mechanical signals influence viral infections in lungs
The process combines virology and mechanobiology, two distinct areas of study that had not been explored at the same time but might prove to be a way to better understand disease progressions to intervene earlier and improve patient outcomes.
-
February 23, 2023
Funding for RIT research tops $92 million
Rochester Beacon highlights RIT’s research portfolio.
-
August 4, 2022
Monkeypox vaccines: A virologist answers 6 questions about how they work, who can get them and how well they prevent infection
The Conversation asks Maureen Ferran, associate professor in the Thomas H. Gosnell School of Life Sciences, about the two vaccines that can protect against monkeypox.
-
April 28, 2022
School of Life Sciences team publishes paper in ‘Biophysical Reports’
-
April 14, 2022
RIT study on prostate cancer treatment underway with $450,000 fund
-
March 4, 2022
Schmitthenner, Ferran, and Sweet win grant
-
January 31, 2022
Omicron: Subvariant BA.2 & CORBEVAX